At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 162 enrolled
Drug / intervention
DDAVP +1 moredrug
Likely dose
DDAVP 0.3 mcg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
1-deamino 8-d-arginine Vasopressin in Percutaneous Ultrasound-guided Renal Biopsy: a Randomized Controlled Trial
In Brief
A Phase 4 clinical trial evaluating DDAVP and saline solution for Kidney Failure. Completed, enrolled 162 participants across 1 site.
Detailed Summary
The investigators evaluated the effect of pre-biopsy treatment with 1-deamino-8-D-arginine (DDAVP) on the incidence of post-biopsy bleeding complications. This is a IV phase single centre, double blind, randomized controlled study in patients, with acute and chronic nephropathy, undergoing ultrasound-guided percutaneous renal biopsy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Failure
CountriesItaly
Collaborators--
Timeline
Phase 4CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2008
First PostedSep 2008
Primary CompletionAug 2009
Study CompletionDec 2009
TodayJul 2026
First PostedSep 8, 2008
Enrollment StartAug 1, 2008
Primary CompletionAug 1, 2009
Study CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 17.8 years ago
Interventions
DDAVPdrug
0.3 mcg/kg subcutaneous
saline solutiondrug
saline solution 1 ml subcutaneous